Salvage Involved-Field and Extended-Field Radiation Therapy in Positron Emission Tomography-Positive Nodal Recurrent Prostate Cancer: Outcomes and Patterns of Failure

Overview

Journal Adv Radiat Oncol

Specialty Oncology

Date 2022 Dec 9

PMID 36483057

Authors

Adeline Petre

Magali Quivrin

Nathalie Briot

Jihane Boustani

Etienne Martin

Igor Bessieres

Alexandre Cochet

Gilles Crehange

Affiliations

Soon will be listed here.

Abstract

Purpose: The optimal salvage pelvic treatment for nodal recurrences in prostate cancer is not yet clearly defined. We aimed to compare outcomes of salvage involved-field radiation therapy (s-IFRT) and salvage extended-field radiation therapy (s-EFRT) for positron emission tomography/computed tomography-positive nodal-recurrent prostate cancer and to analyze patterns of progressions after salvage nodal radiation therapy.

Methods And Materials: Patients with F-fluorocholine or Ga prostate-specific membrane antigen ligand positron emission tomography/computed tomography-positive nodal-recurrent prostate cancer and treated with s-IFRT or s-EFRT were retrospectively selected. Time to biochemical failure, time to palliative androgen deprivation therapy (ADT), and distant metastasis-free survival were analyzed.

Results: Between 2009 and 2019, 86 patients were treated with salvage nodal radiation therapy: 38 with s-IFRT and 48 with s-EFRT. After a median follow-up of 41.9 months (5.4-122.1 months), 47 patients presented a further relapse: 31 after s-IFRT and 16 after s-EFRT, with only 1 in-field relapse. The median time to palliative ADT was 24.8 months (95% confidence interval [CI], 13.3-93.5 months) in the s-IFRT group and not yet reached (95% CI, 40.3 months to not yet reached) in the s-EFRT group ( = .010). The 3-year biochemical failure-free rate was 70.2% (95% CI, 51.5%-82.9%) with s-IFRT and 73.9% (95% CI, 55.4%-85.7%) with s-EFRT ( = .657). The 3-year distant metastasis-free survival was 74.1% (95% CI, 56.0%-85.7%) with s-IFRT and 82.0% (95% CI, 63.0%-91.8%) with s-EFRT ( = .338).

Conclusions: s-EFRT and s-IFRT for positron emission tomography-positive nodal-recurrent prostate cancer provide excellent local control. Time to palliative ADT was longer following s-EFRT than following s-IFRT.

References

Rischke H, Schultze-Seemann W, Wieser G, Kronig M, Drendel V, Stegmaier P . Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only. Strahlenther Onkol. 2014; 191(4):310-20. DOI: 10.1007/s00066-014-0763-5. View

Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiavina R . New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Eur Urol. 2016; 70(1):161-175. DOI: 10.1016/j.eururo.2016.01.029. View

Rouard N, Peiffert D, Rio E, Mahe M, Delpon G, Marchesi V . Intensity-modulated radiation therapy of anal squamous cell carcinoma: Relationship between delineation quality and regional recurrence. Radiother Oncol. 2019; 131:93-100. DOI: 10.1016/j.radonc.2018.10.021. View

Vaugier L, Palpacuer C, Rio E, Goineau A, Pasquier D, Buthaud X . Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07). Int J Radiat Oncol Biol Phys. 2018; 103(5):1061-1067. DOI: 10.1016/j.ijrobp.2018.12.020. View

Shipley W, Seiferheld W, Lukka H, Major P, Heney N, Grignon D . Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med. 2017; 376(5):417-428. PMC: 5444881. DOI: 10.1056/NEJMoa1607529. View

McCormick B, Mahmoud A, Williams S, Davis J . Biochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategies. Indian J Urol. 2019; 35(1):6-17. PMC: 6334583. DOI: 10.4103/iju.IJU_355_18. View

Soldatov A, von Klot C, Walacides D, Derlin T, Bengel F, Ross T . Patterns of Progression After Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018; 103(1):95-104. DOI: 10.1016/j.ijrobp.2018.08.066. View

Kupelian P, Potters L, Khuntia D, Ciezki J, Reddy C, Reuther A . Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2003; 58(1):25-33. DOI: 10.1016/s0360-3016(03)00784-3. View

Bolla M, Collette L, Blank L, Warde P, Dubois J, Mirimanoff R . Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360(9327):103-6. DOI: 10.1016/s0140-6736(02)09408-4. View

10.

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A . Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 36(5):446-453. DOI: 10.1200/JCO.2017.75.4853. View

11.

Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes R . Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2014; 67(5):852-63. DOI: 10.1016/j.eururo.2014.09.004. View

12.

Yang X, Ren H, Yu W, Zhang X, Sun Y, Shao Y . Analysis of Clinical Target Volume Delineation in Local-regional Failure of Nasopharyngeal Carcinoma after Intensity-modulated Radiotherapy. J Cancer. 2020; 11(7):1968-1975. PMC: 7052868. DOI: 10.7150/jca.39588. View

13.

Morris W, Tyldesley S, Rodda S, Halperin R, Pai H, Mckenzie M . Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam.... Int J Radiat Oncol Biol Phys. 2017; 98(2):275-285. DOI: 10.1016/j.ijrobp.2016.11.026. View

14.

Carrie C, Magne N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange J . Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019; 20(12):1740-1749. DOI: 10.1016/S1470-2045(19)30486-3. View

15.

Rozet F, Hennequin C, Beauval J, Beuzeboc P, Cormier L, Fromont-Hankard G . [French ccAFU guidelines - Update 2018-2020: Prostate cancer]. Prog Urol. 2019; 28 Suppl 1:R81-R132. DOI: 10.1016/j.purol.2019.01.007. View

16.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T . EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol. 2016; 71(4):630-642. DOI: 10.1016/j.eururo.2016.08.002. View

17.

Beheshti M, Manafi-Farid R, Geinitz H, Vali R, Loidl W, Mottaghy F . Multiphasic Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients. J Nucl Med. 2020; 61(10):1484-1490. DOI: 10.2967/jnumed.119.238071. View

18.

Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans P . Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. J Clin Oncol. 2016; 34(15):1748-56. DOI: 10.1200/JCO.2015.64.8055. View

19.

Decaestecker K, De Meerleer G, Lambert B, Delrue L, Fonteyne V, Claeys T . Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol. 2014; 9:135. PMC: 4066290. DOI: 10.1186/1748-717X-9-135. View

20.

Ost P, Jereczek-Fossa B, van As N, Zilli T, Tree A, Henderson D . Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences. Clin Oncol (R Coll Radiol). 2016; 28(9):e115-20. DOI: 10.1016/j.clon.2016.04.040. View